title: Serum interleukin-11 in patients with benign prostatic hyperplasia and prostate cancer.
abstract: To clarify whether serum levels of interleukin-11 (IL-11) could be a useful marker in patients with prostate cancer, serum IL-11 was determined in 73 and 23 men with prostate cancer and benign prostate hyperplasia (BPH), respectively, before treatment. There were no statistical differences of IL-11 levels between patients with prostate cancer and BPH. Patients with hormone-resistant prostate cancer had a significantly higher level of IL-11 than those with untreated cancer. Serum IL-11 levels may be a potential tumor marker for prostate cancer progression.
authors.affiliation: Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan. furuyayu@med.teikyo-u.ac.jp
authors.forename: Yuzo
authors.initials: Y
authors.lastname: Furuya
authors.forename: Remon
authors.initials: R
authors.lastname: Nishio
authors.forename: Akira
authors.initials: A
authors.lastname: Junicho
authors.forename: Osamu
authors.initials: O
authors.lastname: Nagakawa
authors.forename: Hideki
authors.initials: H
authors.lastname: Fuse
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D006801:Humans; D017370:Interleukin-11 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood*
chemical_list: D015415:Biomarkers; D017370:Interleukin-11